Introgen to Present ADVEXIN Phase 3 Study Results at Cancer Clinical Trials and Personalized Medicine Conference
News Jul 21, 2008
Introgen Therapeutics, Inc. has announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine.
The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
Introgen’s presentation will review the previously announced findings from the Company’s Phase 3 trial which demonstrated that ADVEXIN successfully achieved its primary and secondary efficacy endpoints in the study’s pre-specified p53 biomarker population.
In addition, Introgen will present supplemental statistical analyses that are included in the Company’s Biologics License Application and Marketing Authorization Application in the U.S. and Europe, respectively.
Low Temperatures Turn Stem Cells into Calorie-Burning FatNews
The secret to healthy eating may not be in freezer food, but low temperatures can help turn stem cells into brown fat, a type of fat which helps burn calories. A new study could turn this knowledge into weight-loss treatments.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE